CoChat

Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis

Open access
Bellos, I., Karageorgiou, V., Pergialiotis, V., Perrea, D.N. · 2020 · Clinical Microbiology and Infection
Cited by 78

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES Acute kidney injury represents a major complication of vancomycin treatment, especially when it is co-administered with other nephrotoxins. This meta-analysis aims to comparatively assess the nephrotoxicity of antipseudomonal beta-lactams when combined with vancomycin. DATA SOURCES Medline, Scopus, CENTRAL and Clinicaltrials.gov databases were systematically searched from inception through 20 August 2019. STUDY ELIGIBILITY CRITERIA Studies evaluating acute kidney injury risk following the concurrent use of antipseudomonal beta-lactams and vancomycin were selected. PARTICIPANTS Adult and pediatric patients treated in hospital or intensive care unit. INTERVENTION Administration of vancomycin combined with any antipseudomonal beta-lactam. METHODS Acute kidney injury incidence was defined as the primary outcome. Secondary outcomes included severity, onset, duration, need of renal replacement therapy, length of hospitalization and mortality. Quality of evidence was assessed using the ROBINS-I tool and the Confidence In Network Meta-Analysis approach. RESULTS Forty-seven cohort studies were included, with a total of 56,984 patients. In the adult population, the combination of piperacillin-tazobactam and vancomycin resulted in significantly higher nephrotoxicity rates compared to vancomycin monotherapy (Odds ratio-OR: 2.05, 95% confidence intervals-CI [1.17-3.46]) and its concurrent use with meropenem (OR: 1.84, 95% CI [1.02-3.10]) or cefepime (OR: 1.80, 95% CI [1.13-2.77]). In pediatric patients, acute kidney injury was significantly higher with vancomycin plus piperacillin-tazobactam than vancomycin alone (OR: 4.18, 95% CI [1.01-17.29]) or vancomycin plus cefepime OR: 3.71, 95% CI [1.08-11.24]). No significant differences were estimated for the secondary outcomes. Credibility of outcomes was judged as moderate, mainly due to imprecision and inter-study heterogeneity. CONCLUSIONS The combination of vancomycin and piperacillin-tazobactam is associated with higher acute kidney injury rates compared to its parallel use with meropenem or cefepime. Current evidence is exclusively observational and is limited by inter-study heterogeneity. Randomized controlled trials are needed to verify these results and define preventive strategies to minimize nephrotoxicity risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmi.2020.03.019

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 78

Metadata

Authors
Bellos, I., Karageorgiou, V., Pergialiotis, V., & Perrea, D. N.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2020-06
Volume
26
Issue
6
Pages
696-705
ISSN
1198-743X (ISSN-L)
OpenAlex
W3013573895
Cited by
78
References
9
FWCI
6.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis. https://app.cochat.ai/papers/10.1016/j.cmi.2020.03.019
The paper
Bellos, I., Karageorgiou, V., Pergialiotis, V., & Perrea, D. N. (2020). Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2020.03.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.